Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973167 | 0.89 | MAPT (0.51) | MAPTALDH1A1HIF1APKMGAA | |
| SCHEMBL3974633 | 0.84 | MAPT (0.48) | MAPTALDH1A1HIF1APKMGAA | |
| SCHEMBL3972253 | 0.84 | CHRM1 (0.46) | MAPTALDH1A1GAACHRM1HRH1 | |
| SCHEMBL4635241 | 0.78 | DPP4 (0.58) | MAPTALDH1A1HIF1APKMGAA | |
| SCHEMBL3971373 | 0.78 | DPP4 (0.62) | MAPTALDH1A1HIF1APKMGAA | |
| SCHEMBL3970466 | 0.75 | MAPT (0.52) | MAPTALDH1A1HIF1APKMGAA | |
| SCHEMBL3969471 | 0.74 | DPP4 (0.58) | MAPTALDH1A1HIF1APKMGAA | |
| SCHEMBL4077418 | 0.74 | DPP4 (0.58) | MAPTALDH1A1HIF1APKMGAA | |
| SCHEMBL3966257 | 0.74 | DPP4 (0.65) | MAPTALDH1A1LMNATSHR | |
| SCHEMBL3966284 | 0.74 | THRB (0.62) | MAPTALDH1A1HIF1APKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569574-B2 | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | disclosed |
| EP-1532150-B1 | NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1532150-A1 | NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
| WO-2004018469-A1 | NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | MAPT 1182/4885ALDH1A1 241/4885HIF1A 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.